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Abstract
Background
The overall aim was to investigate the change over time in circulating cell free DNA (cfDNA)
in patients with locally advanced non-small cell lung cancer (NSCLC) undergoing concurrent
chemo-radiotherapy. Furthermore, to assess the possibility of detecting circulating cell free
tumor DNA (ctDNA) using shallow whole genome sequencing (sWGS) and size selection.
Methods
Ten patients were included in a two-phase study. The first four patients had blood samples
taken prior to a radiation therapy (RT) dose fraction and at 30 minutes, 1 hour and 2 hours
after RT to estimate the short-term dynamics of cfDNA concentration after irradiation. The
remaining six patients had one blood sample taken on six treatment days 30 minutes post
treatment to measure cfDNA levels. Presence of ctDNA as indicated by chromosomal aber-
rations was investigated using sWGS. The sensitivity of this method was further enhanced
using in silico size selection.
Results
cfDNA concentration from baseline to 120 min after therapy was stable within 95% tolerance
limits of +/- 2 ng/ml cfDNA. Changes in cfDNA were observed during therapy with an appar-
ent qualitative difference between adenocarcinoma (average increase of 0.69 ng/ml) and
squamous cell carcinoma (average increase of 4.0 ng/ml). Tumor shrinkage on daily cone
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beam computer tomography scans during radiotherapy did not correlate with changes in
concentration of cfDNA.
Conclusion
Concentrations of cfDNA remain stable during the first 2 hours after an RT fraction. How-
ever, based on the sWGS profiles, ctDNA represented only a minor fraction of cfDNA in this
group of patients. The detection sensitivity of genomic alterations in ctDNA strongly
increases by applying size selection.
Background
Despite advances in curatively intended concurrent chemo-radiotherapy (cCRT), patients
with inoperable NSCLC have a substantial risk of local or distant failure. At present, there are
no liquid biomarkers available to predict treatment response or risk of relapse before or during
cCRT in locally advanced, inoperable NSCLC [1],[2]. A recent report by the American Society
of Clinical Oncology (ASCO) and College of American Pathologists does not recommend clin-
ical implementation of any proposed biomarker due to little, if any evidence of clinical validity
and utility in early stage cancers [3].
Circulating cell free DNA (cfDNA) are small fragments of DNA circulating in the blood
stream and other body fluids. The mechanisms behind DNA release are still debated [4],[5]. It
has been proposed that cfDNA originates from necrotic or apoptotic cells or by active release
mechanisms [6],[7]. Short cfDNA fragments can be detected in plasma from cancer patients
[8],[9] and plasma cfDNA concentrations from healthy individuals are shown to be lower than
in lung cancer patients[10]. cfDNA in patients with disseminated NSCLC has been studied as
a prognostic marker [11], and, a prospective study of 44 patients treated with chemotherapy
could detect a correlation between baseline cfDNA and progression free survival (PFS) [12]. In
addition, the detection of chromosomal instability quantification in plasma cfDNA has been
associated with therapeutic response to immune therapy[13]. However, the use for total
cfDNA measurements is still being investigated. Studies of the plasma levels of cfDNA in
NSCLC patients treated with radiotherapy are sparse [14] and there is an unmet need of evalu-
ating cfDNA analysis in this patient group. Furthermore, the half-life of cfDNA(clearance of
DNA from the blood stream)and thus the adequate timing for blood sample collection remain
unclear [4].
The present study is a prospective two-phase pilot study aiming at: 1) Determination of the
most suitable time point for cfDNA blood sampling after chemo/radiotherapy and, 2) Assess-
ment of changes in cfDNA in patients undergoing cCRT for evaluation of the feasibility of
cfDNA as a potential biological response marker during cCRT. Analysis of ctDNA content in
total cfDNA by shallow whole genome sequencing (sWGS) and in silico size selection was
added for a subset of patients at time-points determined after analysis of cfDNA content.
Methods
Consecutive patients with inoperable locally advanced NSCLC eligible for cCRT were offered
inclusion at their first visit to the Department of Oncology before starting chemotherapy.
Patients were offered 24 hours of consideration and could give their acceptance just before
first cycle of chemotherapy. Patients were enrolled in the study from October 2016 until
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September 2017 at the Department of Oncology, University Hospital of Copenhagen, Rigshos-
pitalet, Denmark. Inclusion criteria were diagnosis of NSCLC, either adenocarcinoma (AC) or
squamous cell carcinoma (SCC), age above 18 years and informed consent. Exclusion criteria
were other active malignancies, antineoplastic treatment other than the scheduled chemo/
radiotherapy for NSCLC, blood transfusion within 3 months of enrolment or, any active
chronic inflammatory diseases e.g. rheumatoid arthritis. Chronic obstructive pulmonary dis-
ease was not considered an exclusion criterion.
All patients signed an informed consent prior to inclusion. The study was approved by the
Danish Ethics Committee, protocol number H-16029201 and the Danish Data Protection
Agency, 2012-58-0004/RH-2016-237/ I-suite no 04837 and by the institutional review board.
Treatment consisted of three cycles of cisplatin or carboplatin in combination with vinorel-
bine concurrent with radiotherapy delivered in 33 2-Gy fractions, five fractions per week to a
total of 66 Gy. Cycles of chemotherapy were given three weeks apart. Radiotherapy started at
the second cycle of chemotherapy and lasted 6.5 weeks. Daily cone beam computer tomogra-
phy (CBCT) scans of the treated tumors were recorded on the linear accelerator to verify
patient position. Total treatment time from first chemotherapy cycle to end radiotherapy was
approximately 9.5 weeks.
Three patients were to be enrolled in part one. Eight blood samples per patient were drawn
as follows. Two samples at baseline (test, retest) before administration of any therapy, one sam-
ple at 30 minutes, 1 and 2 hours after first infusion of cisplatin or carboplatin and one sample
at 30 minutes, 1 and 2 hours after the first 2 Gy fraction on the first day of radiotherapy
(Fig 1).
In part two of the study, six patients were enrolled with blood draws at 30 minutes post irra-
diation. AC and SCC were to be equally distributed with 3 AC and 3 SCC patients. Six blood
samples were drawn during therapy; i.e. blood sample No. 1 was taken at baseline with no
treatment given; sample No. 2 was drawn 1.5 weeks after the first cycle of chemotherapy at the
time of a PET/CT scan for planning radiotherapy. Sample No. 3 was obtained on the first day
of radiotherapy, and three further samples were taken every during radiotherapy: No. 4 after
11 fractions, No. 5 after 22 fractions, and No. 6 after 33rd and final fraction (Fig 1).
Genomic testing
Blood samples were collected in 10 ml cell-free blood collection tubes (Streck1) or PAX tubes
(Qiagen1), containing a preservative, which prevent the release of genomic DNA from blood
cells, thus allowing isolation of cfDNA. Within 1–4 days after collection, plasma was isolated
from the blood samples by centrifugation (2250 x g for 10 min), followed by a second centrifu-
gation step (18000 x g for 10 min). Purification of cfDNA was done from 4 ml plasma using
the QiaSymphony Circulating DNA kit (on the QiaSymphony, Qiagen). The cfDNA was
eluted in a total volume of 60 μl. The cfDNA concentration was measured on the Qubit instru-
ment (Thermo Fisher Scientific) using the double stranded DNA High Sensitivity Assay kit
(Thermo Fisher Scientific). To confirm cfDNA counts to contain DNA from tumor cells, part
two blood samples were analyzed using sWGS assessing somatic copy number alterations
(SCNAs) in a genome-wide manner. Genomic alterations including SCNAs are a key charac-
teristic of the cancer genome [15] and the detection of SCNAs in cfDNA can thus indicate the
presence of tumor DNA in the circulation. The principle of sWGS relies on low-depth (>0.1x)
whole-genome sequencing to estimate the SCNAs from the sequencing read depth [16], [17].
Indexed DNA libraries were constructed from 10 ng of cfDNA using the NEBNext Ultra II
DNA library Prep Kit for Illumina (New England Biolabs) and paired-end sequenced (150-bp)
on the MiSeq or NextSeq platforms (Illumina). Prior to sequencing, the libraries were
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quantified using the high sensitivity dsDNA assay on the Qubit instrument (Thermo Fisher
Scientific) and the fragment size inspected using the Bioanalyzer High Sensitivity DNA Analy-
sis on the 2100 Bioanalyzer Instrument (Agilent). Furthermore, the libraries were pooled in
equimolar amounts with six libraries in each run. A minimum of 5 million reads per sample
were required to evaluate copy number alterations in cfDNA. Analysis of sWGS data was per-
formed using the QDNASeq (https://bioconductor.org/packages/release/bioc/html/
QDNAseq.html) dividing the genome into windows or bins of a certain size, and the GC-cor-
rected read count for each bin is then used to determine if the region is increased or decreased.
Due to the low content of tumor cfDNA in this group of patients, an in silico size selection
algorithm selecting fragments between 90 and 150 bp was applied to increase the detection of
SCNAs [17]. This metric is called trimmed median absolute deviation from copy number neu-
trality (tMAD) and has been described by Mouliere and collegues [17].
Results
Study cohort and feasibility of blood sampling
Ten patients were included in the study, see Table 1. Two patients withdrew from part one of
the study after the first five samples due to the discomfort of blood sampling. Patient no 3 had
a suboptimal blood sample for the baseline re-test and a cfDNA count could not be obtained.
Consequently, an additional patient was included to obtain information on the optimal time
for blood sampling after the first radiotherapy fraction. Sample two from patient no 8 did not
Fig 1. First and second part of cfDNA study. Part 1: Eight blood samples for cfDNA analysis taken in 4 patients at different timepoints during treatment.
Part 2: Six blood samples for cfDNA analysis taken in 6 patients at different time-points during treatment. All samples in part 2 were taken approximately 30
minutes post-irradiation based on the results of part 1.
https://doi.org/10.1371/journal.pone.0231884.g001
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reach the required number of reads (4 million reads), however could be assessed for further
analysis.
Based on data from part one, a scatter plot was produced to identify any dynamics of
cfDNA concentrations when obtaining cfDNA at different time intervals post chemotherapy/
radiotherapy. We saw no evidence of a relevant dynamics of cfDNA at this timescale (<2
hours) in either treatment modalities (Fig 2).
Table 1. Patient, tumor and baseline cfDNA characteristics.
Patient no Age Gender Histology TNM Clinical Stage GTV cm3 Volume cm3 receiving 59.4 Gy Baseline cfDNA ng/ml
1 69 F AC T2N2 IIIA 40 - 5.85
2 69 M SCC T2N2 IIIA 71 - 17.78
3 65 F SCC T3N3 IIIB 144 - 1.50
4 68 F SCC T2N3 IIIB 132 - 4.13
5 69 F AC T4N3 IIIB 153 815 3.60
6 60 F AC T1N3 IIIB 13 166 2.79
7 57 M SCC T4N2 IIIB 290 1088 7.85
8 67 M SCC T2N2 IIIA 158 659 8.27
9 69 M AC T2N2 IIIA 78 422 2.52
10 81 M SCC T4N1 IIIA 49 423 1.47
F: Female. M: Male. AC: Adenocarcinoma. SCC: Squamous cell carcinoma. TNM: Tumor Node Metastasis. All patients were M0. Clinical stage according to 7th version
of UICC: Union for International Cancer Control. GTV: Gross tumor volume of tumor and lymph nodes. Volume cm3 receiving 90% of the prescribed radiation dose
of 66Gy (59.4 Gy). Gy: Gray. -: not relevant. cfDNA: circulating cell free deoxyribonucleic acid. For patient 1–4 cfDNA counts are mean counts from the test and re-test
at baseline.
https://doi.org/10.1371/journal.pone.0231884.t001
Fig 2. Comparison of cfDNA concentrations at several timepoints after infusion of chemotherapy (circles) or first radiotherapy fraction (crosses). Measurement
uncertainty is estimated from test-retest at baseline.
https://doi.org/10.1371/journal.pone.0231884.g002
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A Bland-Altman plot was produced of cfDNA measurements at all time points (baseline
test, retest; after first chemotherapy infusion at 30, 60 and 120 minutes and after first radio-
therapy fraction at 30, 60 and 120 minutes). For each sample, the difference from the mean of
the samples acquired at baseline, after chemotherapy and after radiotherapy, respectively, is
displayed (Fig 3). In the absence of any apparent time-dependence of the cfDNA counts, blood
sampling for part two of the study was determined to be 30 minutes after chemo- or radiother-
apy. The median cfDNA count at baseline in all ten patients was 3.86 ng/ml plasma, range
[1.47–17.78].
Response to radiation therapy and dynamics of cfDNA
Over the course of radiation therapy (from 1st to last 33rd fraction), tumor volume regression
was observed in all 6 patients with a mean decrease of the maximum tumor diameter of 16%,
range [1–24%] measured in one direction of the primary tumor on the CBCT scans (Fig 4, top
row).
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Fig 3. Bland Altman plot of cfDNA concentrations shows detection with 95% tolerance limits of +/- 2 ng/ml cfDNA at baseline, and during the
first 2 hours after treatment of either chemotherapy or radiotherapy. Black horizontal line: Mean difference from a one sample T-test of all 25
samples. Dashed lines: limits of agreements (95%): mean difference +/- (SD�1.96). SD: standard deviation. cfDNA: circulating cell free DNA.
https://doi.org/10.1371/journal.pone.0231884.g003
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When looking at the dynamics of cfDNA, AC and SCC patients displayed different pat-
terns. AC patients had lower mean cfDNA concentration at baseline than SCC, 2.97 and 5.86
ng/ml plasma, respectively. Furthermore, fluctuations in cfDNA during therapy were less pro-
nounced in AC patients compared to SCC patients. For example, the mean increase in cfDNA
from baseline to the 22nd fraction (blood sample no 5) was 0.69 ng/ml range [-2.2 to 3.0] ng/ml
for the three AC patients and 4.0 ng/ml range [-4.3 to 10.8] ng/ml in the three SCC patients
(Fig 4). This difference was not statistically significant, however (Wilcoxon rank sum test; p-
value = 0.7). Noticeably, we observed moderate–if any—correlation between total cfDNA and
tumor shrinkage, Spearman’s rho of 0.54 at 11th fraction and 0.77 at 22nd fraction (S1 Fig).
Dynamics of ctDNA during therapy. To estimate the proportion of cfDNA originating
from tumor (ctDNA), we further assessed the presence of somatic copy number alterations
(SCNAs) using sWGS in 6 patients (Fig 5). Blood samples were obtained at baseline, at the
time of the FDG PET/CT scan for radiotherapy planning, and after the 1st and 11th RT frac-
tion; i.e. 4 samples per patient. However, only two samples from patient 9 were available for
analysis. An additional sample from patient 10 (after 22nd fraction) was included.
In general, samples showed silent profiles across the two cancer types; i.e. no SCNAs were
detected most probably due to the low content of ctDNA in the plasma (Fig 5). However,
patient 7 had segmental amplification on chromosome 7 involving EGFR. The amplification
was detected at baseline and in the following two blood samples. Furthermore, SCNAs were
detected in patient 5 (gain 8q) and patient 9 (gain 5p) after the first fraction of radiotherapy.
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S2 Fig depicts all sWGS reads and corresponding tMAD scores in patients from part two of
the study.
As cfDNA from tumor cells is shorter than cfDNA originating from normal cells [18],[19],
we further applied in silico size selection in order to increase the sensitivity of SCNAs detec-
tion. Using size selection and tMAD scores have shown ctDNA detection down to a minor
allele frequency of 0.01 (1%) [17,20]. Noticeably, processing sWGS data by size selection with
tMAD> 0.015, SCNAs were detected in 16 out of 23 samples (70%) compared to 5 samples
(22%) without size selection (Fig 5). For example, patient 10 showed silent profiles in all sam-
ples by basic sWGS processing. After size selection, SCNAs were found on chromosome 3, 5
and 9 at baseline. After the first round of chemotherapy, i.e. at PET/CT scan, only gain 3q was
present. However, already after the first fraction of radiotherapy, additional aberration on 8q
was revealed, involving MYC amplification (Fig 5). This could indicate possible activation of a
resistance mechanism [21].
Of note, the increase in cfDNA concentration did not reflect the increase in ctDNA content
as indicated by presence of SCNAs. To further examine the reason for increase of normal cell
death, we looked on possible inflammation and/or normal tissue necrosis caused by radiation.
However, leucocytes and platelets tended to decrease during therapy. Leucocytes decreased on
average 5.3 units (std. dev. 1.6) from baseline (at mean 9.3 � 109/l) to measurement between
cfDNA samples four and five (11th to 22nd fraction), p<0.001 for difference. Platelets on aver-
age dropped by 147 units (std. dev. 98 units) from mean 424 (109/l) at baseline with p = 0.014
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for difference in the same time span. For lactate dehydrogenase (LDH), baseline mean was 201
(U/l) and all measured stayed within normal range with p = 0.8 for difference over the time
span. There were no obvious patterns in cfDNA changes during therapy on one hand and the
volume of the body being irradiated or the size of the GTV on the other (S3 and S4 Figs).
Patient treatment outcome. Patient no 5 with AC was diagnosed with multiple brain
metastases during radiotherapy, at the time around 22nd fraction (blood sample 5). She com-
pleted cCRT and was given whole brain radiation hereafter. She died six months post therapy.
Patient no 6 was offered surgery after cCRT. Histology showed active adenocarcinoma in the
primary tumor and affected lymph node. At the latest follow up seven months after, she was
tumor free assessed from a PET/CT scan. Patient no 9 also received salvage surgery after com-
pletion of cCRT. Histology showed active AC in the right upper lobe. Lymph node stations 4
and 10 were without tumor cells after cCRT. He was without any evidence of disease six
months post cCRT and will be offered three additional cycles of chemotherapy. Patient no 7
had loco-regional relapse two months after cCRT. Patient no 8 had surgery post cCRT. Histol-
ogy from the operated lobe showed active squamous cell carcinoma in the primary tumor.
Lymph nodes were without cancer cells. He was without any evidence of disease eight months
post cCRT. Patient no 10 completed cCRT but died ten days later. In conclusion, after comple-
tion of cCRT, five out of six patients had active disease, either by clinical and radiological pro-
gression or pathological examination at surgery.
Discussion
This pilot study shows that cfDNA concentrations in patients undergoing cCRT can be
assessed with stable cfDNA measurements from 30 to 120 minutes after a radiation therapy
fraction. Concentrations of cfDNA during treatment showed mean increases above the 95%
tolerance limits of +/- 2 ng/ml cfDNA established in part 1 in SCC patients, whereas cfDNA
changes in AC stayed within the tolerance limits. sWGS analyses could not confirm that
observed cfDNA changes represent changes in ctDNA content. In most cfDNA samples, no
genomic alterations were detected after the 11th fraction. However, size selection with tMAD
scores found surprisingly more ctDNA in most samples. It further confirmed the sWGS
results, that ctDNA was not the cause of high cfDNA levels past the 11th fraction of radiother-
apy, as the tMAD scores were below 0.015 for the remaining course of radiotherapy. However,
patient cases illustrate that for most tumors, ongoing activity was observed in five out of six
patients post cCRT. A silent ctDNA profile did not seem to correspond to clinical outcome of
the patients. Likewise, there was no concordance between radiological response and cfDNA
change during treatment. Generally, the volume of the primary tumor on CBCT decreased but
the cfDNA counts increased during therapy in both SCC and AC patients. Interestingly,
patient 5 had low cfDNA counts with only one sample showing a chromosome 8 amplification
during therapy. She had a marked decrease in chest tumor size, yet multiple brain metastases
were discovered around the time of the 22nd fraction.
How radiotherapy influences the tumor cells and surrounding normal tissue to release
DNA remains to be clarified. One hypothesis is that cfDNA counts increase as more and more
tumor cells are exposed to ionizing radiation hereby releasing DNA into the blood stream. A
quantitative assessment of tumor DNA as a proportion of cfDNA counts is currently under
investigation as the sensitivity of sWGS in detecting ctDNA among high cfDNA levels is still
not clear. This pilot study was not powered to detect a pre-specified difference in the cfDNA
profile in SCC versus AC, nor to detect a possible correlation between cfDNA differences in
AC and SCC, but the observed patterns are interesting for future studies and suggest that the
two histologies should be separated in future analyses.
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In conclusion, future studies of cfDNA could conveniently be conducted with blood sam-
ples obtained approximately 30 minutes post chemo- and radiotherapy treatment, and moder-
ate variation in sample timing does not appear to affect results. cfDNA concentrations change
during therapy beyond the sample-to-sample variability. However, more studies are needed to
clarify if these changes are of value in guiding further therapy and to understand the mecha-
nism behind cfDNA release during therapy.
Supporting information
S1 Fig. Scatter plot of cfDNA change as a function of tumor shrinkage measured on CT. •:
Tumor change from PET/CT scan (blood sample no 2) to fourth cfDNA blood sample (11th
fraction). +: Tumor change from PET/CT scan (blood sample no 2) to fifth cfDNA blood sam-
ple (22nd fraction). cfDNA: circulating cell-free DNA.
(PDF)
S2 Fig. All sWGS reads following the in silico size selection data with tMAD scores in
patients from part 2 of the study.
(PDF)
S3 Fig. Scatter plot of volume [cm3] of the body receiving 59.4 Gy (90% of the prescribed
66 Gy) and a function of cfDNA change. Gy: Gray. cfDNA: circulating cell free DNA. PET/
CT: positron emission tomography/computer tomography.
(PDF)
S4 Fig. Scatter plot of cfDNA level change as a function of GTV divided by histology.
cfDNA: circulating cell free DNA. GTV: Gross tumor volume. PET/CT: positron emission
tomography/computer tomography. SCC: Squamous cell carcinoma. AC: Adenocarcinoma.
(PDF)
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